EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor‐Beta in Liver Tumorigenesis

Ana Cantos-Cortes, Josep Amengual, Rut Espinosa-Sotelo, Esther Bertran, Javier Vaquero, Marina Ruiz de Galarreta, Pedro Molina-Sanchez, Teresa Serrano, Emilio Ramos, Mariona Calvo, Rosanna Scialpi, Francesco Dituri und 4 weitere

Liver International · 2025

DOI: 10.1111/liv.70351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Ana Cantos-Cortes und 15 weiteren Autor:innen. Beteiligte Einrichtung: TGF-Beta and Cancer Group - Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Carcinoma, Hepatocellular, Liver Neoplasms, Carcinogenesis. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundación Científica Asociación Española Contra el Cáncer, Ministerio de Ciencia e Innovación, Direcció General de Recerca, Generalitat de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options. TGF‐β is a promising therapeutic target, but its dual role, as both a tumour suppressor and promoter, complicates its clinical application. While its effects on tumour cells are increasingly understood, its impact on the tumour stroma remains unclear. This study developed novel in vitro and in vivo mouse models to investigate the role of TGF‐β in tumour–stroma interactions under immunocompetent conditions, aiming to evaluate its therapeutic potential in liver cancer.

Methods

Mouse liver tumour cell lines were established by hydrodynamic tail vein injection of two different combinations of transposon vector constructions: MYC ‐ LucOS;CTNNB1;SB13 (AL1099 cells) and MYC ‐ Luc;CTNNB1;SB13 (AL1184 cells) to be used in in vitro and in vivo studies.

Results

These cell lines exhibited contrasting phenotypes and responses to TGF‐β. We selected AL1099 cells, which displayed an epithelial phenotype and responded to TGF‐β with growth inhibition, apoptosis, and induction of Epithelial‐Mesenchymal Transition (EMT), and AL1184 cells, which exhibited a mesenchymal‐like phenotype and showed enhanced proliferation in response to TGF‐β. Both cell lines demonstrated robust growth in 2D and 3D cultures and were co‐cultured with RAW 264.7 macrophages, GRX hepatic stellate cells, or both, to explore tumour‐stroma interactions. Importantly, AL1099 and AL1184 cells were able to grow in vivo, forming tumours in syngeneic orthotopic models suitable for pharmacological studies.

Conclusions

Together, these findings highlight the value of these models for advancing therapeutic strategies targeting TGF‐β, either alone or in combination with immunotherapy, in liver cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor betaCarcinoma, HepatocellularLiver NeoplasmsCarcinogenesisAnimalsMiceEpithelial-Mesenchymal TransitionCell Line, TumorDisease Models, AnimalApoptosisCell ProliferationHumans

Stichwörter der Autor:innen

hepatic stellate cellshepatocellular carcinomamacrophagessyngeneic liver tumour

Substanzen

Transforming Growth Factor beta

Autor:innen und Institutionen

  • TGF-Beta and Cancer Group - Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III, Madrid, Spain.
  • HepatoBiliary Tumours Lab, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain.
  • Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • University Hospital of Bellvitge HUB and Faculty of Medicine and Health Sciences-University of Barcelona (UB), Barcelona, Spain.
  • Oncología Médica, Institut Català d'Oncologia (ICO-IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.

ORCID-Profile: Ester Gonzalez-Sanchez, Isabel Fabregat

Förderung

  • Fundación Científica Asociación Española Contra el Cáncer
  • Ministerio de Ciencia e Innovación
  • Direcció General de Recerca, Generalitat de Catalunya
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
  • Ministerio de Ciencia, Innovación y Universidades

Zitieren

APA

Cantos-Cortes, A., Amengual, J., Espinosa-Sotelo, R., Bertran, E., Vaquero, J., de Galarreta, M. R., Molina-Sanchez, P., Serrano, T., Ramos, E., Calvo, M., Scialpi, R., Dituri, F., Giannelli, G., Lujambio, A., Gonzalez-Sanchez, E., & Fabregat, I. (2025). New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor‐Beta in Liver Tumorigenesis. Liver International. https://doi.org/10.1111/liv.70351

Vancouver

Cantos-Cortes A, Amengual J, Espinosa-Sotelo R, Bertran E, Vaquero J, de Galarreta MR, et al. New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor‐Beta in Liver Tumorigenesis. Liver International. 2025. doi:10.1111/liv.70351

BibTeX
@article{CantosCortes2025,
  author = {Cantos-Cortes, Ana and Amengual, Josep and Espinosa-Sotelo, Rut and Bertran, Esther and Vaquero, Javier and de Galarreta, Marina Ruiz and Molina-Sanchez, Pedro and Serrano, Teresa and Ramos, Emilio and Calvo, Mariona and Scialpi, Rosanna and Dituri, Francesco and Giannelli, Gianluigi and Lujambio, Amaia and Gonzalez-Sanchez, Ester and Fabregat, Isabel},
  title = {New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor‐Beta in Liver Tumorigenesis},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70351}
}
Kostenlos starten →